Business Description
scPharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US8106481059
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.43 | |||||
Equity-to-Asset | 0.31 | |||||
Debt-to-Equity | 1.66 | |||||
Debt-to-EBITDA | -0.84 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -4.24 | |||||
Beneish M-Score | 4.67 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -0.2 | |||||
3-Year EPS without NRI Growth Rate | -2.7 | |||||
3-Year FCF Growth Rate | -10.9 | |||||
3-Year Book Growth Rate | -29.9 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 50.5 | |||||
9-Day RSI | 49.51 | |||||
14-Day RSI | 48.35 | |||||
6-1 Month Momentum % | -18.04 | |||||
12-1 Month Momentum % | -57.99 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.21 | |||||
Quick Ratio | 5.44 | |||||
Cash Ratio | 4.74 | |||||
Days Inventory | 511.75 | |||||
Days Sales Outstanding | 78.87 | |||||
Days Payable | 188.46 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.6 | |||||
Shareholder Yield % | -8.98 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 71.69 | |||||
Operating Margin % | -338.58 | |||||
Net Margin % | -327.29 | |||||
FCF Margin % | -343.15 | |||||
ROE % | -115.34 | |||||
ROA % | -55.43 | |||||
ROIC % | -704.4 | |||||
ROC (Joel Greenblatt) % | -939.3 | |||||
ROCE % | -52.62 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 10.46 | |||||
PB Ratio | 6.98 | |||||
Price-to-Tangible-Book | 6.63 | |||||
EV-to-EBIT | -2.59 | |||||
EV-to-Forward-EBIT | -7.14 | |||||
EV-to-EBITDA | -2.62 | |||||
EV-to-Revenue | 7.25 | |||||
EV-to-Forward-Revenue | 3.95 | |||||
EV-to-FCF | -2.54 | |||||
Price-to-Net-Current-Asset-Value | 7.19 | |||||
Price-to-Net-Cash | 35.33 | |||||
Earnings Yield (Greenblatt) % | -38.6 | |||||
FCF Yield % | -41.52 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
scPharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 16.273 | ||
EPS (TTM) (€) | -1.368 | ||
Beta | 0.18 | ||
Volatility % | 52.78 | ||
14-Day RSI | 48.35 | ||
14-Day ATR (€) | 0.193712 | ||
20-Day SMA (€) | 4.233 | ||
12-1 Month Momentum % | -57.99 | ||
52-Week Range (€) | 3.82 - 10.9 | ||
Shares Outstanding (Mil) | 36.05 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
scPharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
scPharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
scPharmaceuticals Inc Frequently Asked Questions
What is scPharmaceuticals Inc(FRA:2SX)'s stock price today?
When is next earnings date of scPharmaceuticals Inc(FRA:2SX)?
Does scPharmaceuticals Inc(FRA:2SX) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |